Current KOL-Pharma Relationship Examined in New FirstWord Study Published at MarketPublishers.com14 Mar 2012 • by Natalie Aster
LONDON – With the implementation this year of the Physician Payment Sunshine Act (PPSA), that role of the key opinion leader (KOL) is about to come under scrutiny once again.
In which areas is the pharmaceutical industry not fully utilizing KOLs and what new avenues can be created to do so? What are the reasons for KOLs' widespread disagreement with the PPSA? How have staff cutbacks in the pharmaceutical industry affected KOL collaboration? To what extent do KOLs want more involvement in drug-development work? How can the industry improve engagement, collaboration and feedback with KOLs? Answers to all these critical questions and many more can be found in the research study.
New research study “Meeting KOL Needs: What Pharma Needs to Know” drawn up by FirstWord has been recently published by Market Publishers Ltd.
Meeting KOL Needs: What Pharma Needs to Know
Published: February, 2012
Price: US$ 1.445,00
The study taps into the mindsets of 33 leading international KOLs to discover how they view their industry work and where they want — and need — their collaborations to go.
- insight on how the forthcoming PPSA will affect KOL-industry ties;
- discussion by KOLs on how pharma can best utilize their expertise in trial design and drug development;
- analysis of core issues facing KOL-industry relations and how to move forward;
- unparalleled access to KOL views on collaboration, diminishing pharma industry contacts, post-trial feedback, the use of digital media and the development of new technologies and therapies.
More new research studies by the publisher can be found at FirstWord page.